Ro vs Hers GLP-1: Which Weight Loss Program Is Better in 2026?

What Changed in 2026 — and Why Most Comparison Pages Are Already Wrong

If you've been searching “Ro vs Hers” and reading pages that say things like “Ro only offers injections” or “Hers is mostly compounded semaglutide” — those pages are outdated. Here's what actually happened:

Hers Just Partnered With Novo Nordisk

On March 9, 2026, Hims & Hers announced a collaboration with Novo Nordisk to bring FDA-approved Wegovy (injections and tablets) and Ozempic (injections) directly to the Hers platform later this month.

As part of this deal, the company said it plans to stop advertising compounded GLP-1 offerings on its platform and in its marketing. Compounded semaglutide will still be available on a limited basis when a provider determines it's clinically necessary.

However, as of March 10, 2026, Hers' live pricing pages still publicly list compounded GLP-1 and compounded GLP-1 microdose plans starting at $199/month. The transition is underway, not complete.

What this means for you: Hers is actively evolving from a primarily compounded GLP-1 platform to one offering both branded and compounded paths. If you sign up now, your provider will evaluate which medication is clinically appropriate for you — and branded options are expanding rapidly.

Ro Now Offers the Wegovy Pill

Older comparison pages say “Ro is injections only.” That hasn't been true since January 2026, when the FDA approved the Wegovy pill (oral semaglutide 25mg) and Ro began offering it.

FDA Tightened Scrutiny on Compounded GLP-1s

The FDA determined the semaglutide injection shortage was resolved in February 2025 and the tirzepatide injection shortage in late 2024. In February 2026, the FDA announced it intended to take action against mass-marketed non-FDA-approved GLP-1 drugs. The agency also sent warnings to telehealth firms about illegally marketing compounded GLP-1 products.

This regulatory pressure is a major reason behind Hers' pivot toward branded medications — the landscape is changing quickly.

Why This Matters for Your Decision Right Now

The timing is actually in your favor. If you'd searched for this comparison six months ago, you would have found a simpler (but less useful) picture: Hers was the affordable compounded option, Ro was the insurance-and-branded option, and that was that.

Today, the lines are blurring — and that's good for you as a consumer. Hers is adding branded access. Ro already has oral options. Competition is driving both platforms to improve. The key is understanding which platform's current strengths match your current needs.

Which One Should You Choose?

What Hers Actually Costs

Hers doesn't charge a membership fee, which immediately simplifies the math. But pricing depends on which medication path you're prescribed and how long you commit. Here's what Hers' public pricing pages show as of March 10, 2026:

What “starting at” really means: The lowest advertised monthly prices require paying for the full plan duration upfront. Monthly billing costs more. Read the payment terms carefully before committing. This is one of the most common friction points in user reviews — but it also protects you from mid-treatment price increases.

HSA/FSA: Eligibility varies by plan provider. Check with your benefits administrator. For more on tax-advantaged accounts, see our GLP-1 HSA/FSA guide.

What Real Hers Customers Say

All testimonials below are disclosed as paid by Hers. Individual results vary.

That last testimonial is worth sitting with. GLP-1s are powerful tools, but they're not magic. The people who get the best results pair their medication with real habit changes — more protein, regular movement, better sleep. The medication handles the hunger and the cravings. You handle the choices.

What Ro Actually Costs

Ro uses a two-layer pricing model: membership fee plus separate medication costs.

Layer 1: The Membership

• First month: $45
• Ongoing: $145/month
• Ro says you can cancel at any time

The membership covers your provider visits, coaching, the Ro app, and the insurance concierge service. It does not include medication.

Layer 2: Medication (Varies Widely)

Source: ro.co/weight-loss/pricing, accessed March 10, 2026. Some prices reflect limited-time promos with specific expiration dates — verify before committing.

With insurance: Copays vary by plan. Commercially insured patients may also have access to manufacturer savings programs that can further reduce costs. Ro's concierge handles the paperwork.

What Ro Members Say

Ro discloses that members were paid for their testimonials.

“I was not expecting insurance help. Usually patients are their own advocate, so I was thrilled to not have to fight for my coverage.” — Hannah, Ro member (paid testimonial via ro.co)

Ro vs Hers: The Real Cost Math

This is the section most comparison pages skip. We ran illustrative numbers for common scenarios. All figures are illustrative as of March 10, 2026 and will change as promos expire and pricing evolves.

The Takeaway

The right choice depends on your specific path:

• Cheapest non-injection start: Hers oral medication kits ($69/mo)
• Cheapest GLP-1 injection (cash-pay): Hers compounded semaglutide ($199/mo, while still available)
• Cheapest branded GLP-1 (cash-pay): Ro, based on current public pricing
• Cheapest branded GLP-1 (insured): Ro with insurance coverage
• No membership fee, all-in pricing: Hers

One pattern we see repeatedly: people start their research focused on the cheapest possible monthly number. But the smarter question is “what will I actually spend over 6–12 months of treatment?” GLP-1 medications aren't a two-week experiment. They work best with sustained use. The platform with the lowest month-one cost isn't always the platform with the lowest total cost over a meaningful treatment period.

For cash-pay patients who want GLP-1 treatment specifically (not oral kits), Hers' compounded semaglutide at $199/month is the current low-cost entry point. But as compounded availability tightens, the branded pricing landscape — where Ro currently has a significant cash-pay advantage — becomes more important to understand.

If you have decent insurance, don't skip the coverage check. Even a moderate copay through Ro's concierge model can make brand-name medication more affordable than any cash-pay alternative on either platform.

Hidden Cost Checklist (For Either Platform)

Before you sign up for any telehealth GLP-1 program, ask yourself:

• Is there a separate membership or platform fee?
• Is medication included in the quoted price, or separate?
• Does the advertised price require upfront payment?
• What happens to pricing when I move from starter to maintenance doses?
• Is lab work required, and is it included?
• What are the shipping costs?
• What's the cancellation and refund policy?
• If my insurance denies coverage, what's my fallback?

What Medications Can You Actually Get?

Not all GLP-1 options are the same — and comparing a $69/month oral medication kit to a branded Wegovy prescription is like comparing a bicycle to a motorcycle. Both get you somewhere. The speed and experience are very different.

Through Ro

Ro's current public pricing pages emphasize FDA-approved branded options:

• Wegovy (semaglutide) — injection: Weekly self-injection. FDA-approved for weight loss and cardiovascular risk reduction.
• Wegovy (semaglutide) — tablet: Daily pill, FDA-approved December 2025. First oral GLP-1 approved for weight management.
• Zepbound (tirzepatide) — injection: Weekly self-injection. A dual-action GIP/GLP-1 agonist.
• Ozempic (semaglutide) — injection: FDA-approved for type 2 diabetes; may be prescribed off-label for weight management.

Note: Ro's terms indicate that members may be prescribed compounded medication during national drug shortages. However, Ro's current public marketing centers on branded options.

Through Hers

Hers' medication menu is evolving due to the Novo Nordisk partnership. Currently listed publicly:

• Compounded semaglutide injections — starting at $199/mo. Not FDA-approved. FDA does not evaluate compounded drugs for safety, effectiveness, or quality.
• Compounded GLP-1 microdose — starting at $199/mo.
• Generic liraglutide — starting at $299/mo.
• Oral medication kits — from $69/mo. May include bupropion, metformin, naltrexone, topiramate, B12. These are not GLP-1 medications.
• Branded Wegovy — ~$1,999/mo
• Branded Ozempic — ~$1,799/mo
• Branded Mounjaro — ~$1,899/mo
• Branded Zepbound — ~$1,899/mo

Coming via Novo Nordisk collaboration (later this month): Ozempic injections, Wegovy injections, and Wegovy tablets at self-pay prices expected to be consistent with other telehealth channels.

The Apples-to-Oranges Trap Most Comparison Pages Fall Into

A $69/month oral kit is not an apples-to-apples comparison with branded Wegovy. A $199/month compounded semaglutide plan is not the same comparison as a branded GLP-1 cash-pay plan. And a $1,999/month branded Wegovy through Hers is a fundamentally different proposition than a $349/month Wegovy pen through Ro.

When you compare costs, make sure you're comparing the same type of treatment. For a deeper look at compounded vs brand-name medications, see our compounded semaglutide safety guide.

The bottom line: understand what category of medication you're comparing before you compare prices. A table that puts “$69/month” next to “$349/month” without explaining that these are completely different classes of medication isn't helping you — it's misleading you. For a detailed medication comparison, see our semaglutide vs tirzepatide guide.

How Fast Can You Start?

What the Onboarding Actually Feels Like

With Hers, the async intake feels like a thorough doctor's form, not a three-question quiz. No video call means no scheduling friction — if you've ever put off a doctor's appointment because scheduling felt like too much, you'll appreciate the approach.

With Ro, the insurance route takes longer, but there's an upside: you're not doing any of the paperwork. Anyone who's ever spent 45 minutes on hold with their insurance company will understand the value of having someone else handle prior authorizations.

What Support Do You Get After You're Prescribed?

A prescription is the beginning, not the end. What happens in the weeks and months after you start matters enormously for whether you stick with treatment long enough to see real results.

Which Approach Is Better?

Hers' model is lighter-touch and self-directed. It works well if you're self-motivated and mainly need medication access, a provider on standby, and tracking tools.

Ro's model is more structured. It works well if you want scheduled accountability, coaching, and someone actively managing your insurance.

Neither is right or wrong — it's a personality and lifestyle fit. Some people thrive with autonomy. Others need the nudge of a scheduled check-in. Know which one you are before you choose.

Specific Situations: Who Wins When

Side Effects: What to Actually Expect

The Common Stuff

The most frequently reported side effects across all GLP-1 medications are gastrointestinal: nausea, vomiting, diarrhea, constipation, and stomach pain. These are typically mild to moderate, worst during the first few weeks or dose increases, and usually improve as the body adjusts.

In the OASIS 4 trial for the Wegovy pill, 74% of participants on oral semaglutide experienced GI side effects compared to 42% on placebo. Serious adverse events were less common in the treatment group (3.9%) than the placebo group (8.8%). For a detailed look, see our GLP-1 side effects guide.

How Each Platform Helps

Hers: Qualifying weight-loss customers may be eligible for ondansetron (generic Zofran) at no additional cost. This is a practical differentiator — nausea is the #1 reason people consider stopping GLP-1 treatment early, and having anti-nausea support can make the difference between pushing through and giving up.

Ro: Regular check-ins with your care team, dose titration adjustments, and metabolic testing at intake may also help your provider customize your treatment plan.

The Serious Warnings

GLP-1 medications carry a boxed warning about the risk of thyroid C-cell tumors, based on animal studies. Anyone with a personal or family history of medullary thyroid cancer (MTC) or MEN 2 should not take these medications. Other serious but uncommon risks include pancreatitis, gallbladder problems, kidney issues, and low blood sugar.

This is not meant to scare you. Millions of people take GLP-1s safely. But disclose your full medical history and report any unusual symptoms immediately. For more detail, see the GLP-1 contraindications guide.

How Much Weight Can You Realistically Expect to Lose?

The drug produces the results. The platform is how you access the drug. Here's what the clinical trials show:

• Semaglutide 2.4mg injection (Wegovy): Average ~15% body weight loss over 68 weeks. One in three participants lost 20% or more. (STEP 1 trial, NEJM)
• Semaglutide 7.2mg injection (investigational higher dose): Average ~21% body weight loss over 72 weeks. (STEP UP trial, 2025 ADA)
• Oral semaglutide 25mg (Wegovy pill): Average ~16.6% body weight loss over 64 weeks with full adherence. (OASIS 4 trial, NEJM)
• Tirzepatide (Zepbound): Average 15–22% body weight loss depending on dose, over 72 weeks. (SURMOUNT-1 trial, NEJM)

For a 220-pound person, 15% = 33 lbs. At 20%, that's 44 lbs.

What Happens When You Stop?

Published research shows that after stopping semaglutide, patients regained approximately two-thirds of their lost weight within one year. GLP-1 treatment is designed to be long-term — paired with the lifestyle changes that help maintain results.

Here's the reframe that matters: needing long-term treatment isn't a failure. It's how chronic conditions work. Blood pressure medication, cholesterol medication — most medications for chronic conditions require ongoing use. Obesity is increasingly recognized as a chronic condition that responds to sustained treatment, not a moral failing to be “fixed” once.

What Makes the Real Difference in Outcomes

The people who lose the most weight and keep it off do four things:

Safety and the Brand-Name vs. Compounded Reality Check

What “Compounded” Actually Means

Compounding is the process of combining, mixing, or altering ingredients in medications for individual patients. Under U.S. law, §503A compounders are licensed pharmacists in state-licensed pharmacies. §503B outsourcing facilities are FDA-registered. These are different categories with different oversight levels.

During the semaglutide and tirzepatide shortages (2022–2025), compounding pharmacies were authorized to prepare GLP-1 medications. The FDA resolved the semaglutide injection shortage in February 2025 and the tirzepatide shortage in late 2024. Since then, the FDA has announced it intends to take action against non-FDA-approved GLP-1 drugs being mass-marketed.

What the FDA Says

The FDA does not approve compounded drugs. They are not evaluated for safety, effectiveness, or quality through the FDA's standard process. With shortages resolved, compounding pharmacies can no longer routinely make copies of commercially available GLP-1s — except in limited cases where a provider documents patient-specific medical necessity.

What This Means for Your Decision

The Hers × Novo Nordisk partnership directly addresses these concerns. By pivoting toward FDA-approved branded medications, Hers is aligning with the direction the FDA and the market are moving.

Ro has always emphasized FDA-approved branded medications in its public marketing — though its terms do acknowledge that compounded medication may be prescribed in shortage situations.

Our take: The compounded vs. branded question is not minor. But here's the broader context: Hers, a publicly traded company (NYSE: HIMS), just partnered with the manufacturer of Wegovy and Ozempic. That partnership signals a clear commitment to meeting the FDA's standard going forward. It doesn't erase the regulatory history, but it does show the company is moving — fast — toward the same standard Ro has operated under.

Reviews, Testimonials, and What People Actually Worry About

How to Read Reviews in This Space

Both Ro and Hers disclose that their featured testimonials are from members who were compensated. That doesn't mean the experiences aren't real — but these are curated success stories, not random samples. The most useful signals come from consistent patterns across multiple sources.

Where Each Platform Falls Short

Hers Weaknesses

Ro Weaknesses

Before You Sign Up: A Pre-Decision Checklist

Before you commit to either platform, take five minutes to work through these questions. They'll save you from the most common regrets we see in user feedback.

How We Compared Ro and Hers

Transparency matters — especially on a page with affiliate links. Here's our process:

• We reviewed current pricing and product pages directly from ro.co and forhers.com (verified March 10, 2026)
• We verified the Hers × Novo Nordisk partnership through the official BusinessWire press release, Novo Nordisk's confirmation, and third-party reporting
• We reviewed FDA prescribing information for Wegovy, Zepbound, and Ozempic
• We reviewed published clinical trial data from STEP 1, STEP UP, OASIS 4, SURMOUNT-1, and SELECT
• We reviewed customer feedback from official platform testimonials and public discussion forums
• We did not receive free products or preferential treatment from either company
• We earn affiliate commissions from some links — but we recommend Ro for some readers and Hers for others because that's the honest answer

Our evaluation criteria:

• Total cost and pricing clarity — 30%
• Medication flexibility and form factor — 25%
• Support and convenience — 15%
• Insurance navigation — 15%
• Safety and transparency — 10%
• Speed to treatment — 5%

Our comparison follows the WPG methodology. Correction policy: If we get something wrong, email us. We'll fix it within 24 hours and note the correction.

Frequently Asked Questions

Final Verdict

Both Ro and Hers are legitimate platforms with real healthcare providers. The clinical evidence behind GLP-1 medications is strong — these drugs help people lose meaningful weight when paired with lifestyle changes. The question was never whether to start. It was where.

If you're still on the fence: Start with whichever one feels less risky to you. You can always switch later. The most important step isn't choosing the perfect platform — it's choosing to start. Every month you delay is a month you could have been building momentum toward the version of yourself you're imagining right now.

Either way, you're making a decision your future self will thank you for.

Sources & References

1. Hers self-reported customer data: Based on self-reported data from 13,458 weight loss customers on personalized treatment plans including compounded GLP-1 injections, reduced-calorie diet, and exercise. Paid testimonials; not independently verified. Source: forhers.com
2. Published drug-trial benchmarks: STEP 1 (Wilding et al., NEJM 2021), SURMOUNT-1 (Jastreboff et al., NEJM 2022).
3. Hims & Hers × Novo Nordisk: “Hims & Hers Announces Strategic Shift for US Weight Loss Business.” BusinessWire, March 9, 2026. investors.hims.com. Novo Nordisk confirmation: novonordisk.com press release, March 9, 2026.
4. Ro pricing and program: ro.co/weight-loss/pricing and ro.co/weight-loss/how-it-works. Accessed March 10, 2026.
5. FDA enforcement: “FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs.” FDA.gov, February 2026.
6. Hers pricing and program: forhers.com/weight-loss/drug-pricing and forhers.com/weight-loss. Accessed March 10, 2026.
7. Hers customer testimonials: forhers.com/blog/semaglutide-before-and-after. Disclosed as paid.
8. Ro program details: ro.co/weight-loss/insurance and ro.co/weight-loss/how-it-works. Accessed March 10, 2026.
9. Wegovy (semaglutide) injection prescribing information. FDA.gov. STEP 1: Wilding JPH et al., NEJM 2021;384(11):989–1002.
10. Wegovy (semaglutide) oral tablet: OASIS 4 trial. Wharton S et al., NEJM 2025.
11. Zepbound (tirzepatide) prescribing information. FDA.gov. SURMOUNT-1: Jastreboff AM et al., NEJM 2022;387(4):327–340.
12. STEP UP trial: Semaglutide 7.2mg. Presented 2025 ADA Scientific Sessions.
13. Weight regain: Wilding JPH et al., “Weight regain and cardiometabolic effects after withdrawal of semaglutide.” Diabetes Obes Metab 2022.
14. FDA compounding oversight: fda.gov/drugs/human-drug-compounding/compounding-inspections-and-oversight-frequently-asked-questions
15. FDA shortage resolution: Semaglutide injection shortage resolved February 21, 2025. Tirzepatide injection shortage resolved December 19, 2024.